AstraZeneca has invested $200m in a new manufacturing facility in China Medical City, Taizhou, Jiangsu province. The new plant will manufacture both intravenous and oral solid medicines.According to the company, the new plant will help meet the rising demand for its products in China besides extending its availability in urban and rural communities that have limited access to established medicines.

The global contract manufacturing will reach $64.07bn in 2016, according to a new report by London-based business information company Visiongain. The report, 'Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021,' says that the market will grow with a CAGR of 8.7% between 2010 and 2016, with finished dosage forms manufacturing driving the revenue growth.

More Articles ...

Subscribe to our Newsletter
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok